Workflow from Scientific Research

PRIME2. No patients were lost to follow-up at the time of the cutoff date. * Low-to-medium potency TCS/TCI as background therapy permitted (maintain dose from screening to EOT). No discontinuations related to COVID-19. Patient could not continue the self-administration of investigational medicinal product. None of the ‘other’ reasons for permanent study intervention discontinuation was related to safety or lack of efficacy. All were reported as the reason for withdrawal by the subject.

DOI